<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">99</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2013-9-2-69-72</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL CASE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">DIAGNOSIS AND TREATMENT OF METACHRONOUS TESTICULAR CANCER: A CLINICAL CASE</article-title><trans-title-group xml:lang="ru"><trans-title>ДИАГНОСТИКА И ЛЕЧЕНИЕ МЕТАХРОННОГО РАКА ЯИЧЕК. КЛИНИЧЕСКИЙ СЛУЧАЙ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kalpinsky</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Калпинский</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>byalerseev@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pryadilova</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Прядилова</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>byalerseev@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kaprin</surname><given-names>A. D.</given-names></name><name xml:lang="ru"><surname>Каприн</surname><given-names>А. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>byalerseev@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alekseev</surname><given-names>B. Ya.</given-names></name><name xml:lang="ru"><surname>Алексеев</surname><given-names>Б. Я.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>byalerseev@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">P.A. Herzen Moscow Oncology Research Institute</institution></aff><aff><institution xml:lang="ru">МНИОИ им. П.А. Герцена</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-06-30" publication-format="electronic"><day>30</day><month>06</month><year>2013</year></pub-date><volume>9</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>69</fpage><lpage>72</lpage><history><date date-type="received" iso-8601-date="2014-07-27"><day>27</day><month>07</month><year>2014</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/99">https://oncourology.abvpress.ru/oncur/article/view/99</self-uri><abstract xml:lang="en"><p>The incidence of bilateral testicular cancer is 5% in the total cohort of patients. Synchronous and metachronous testicular cancers are detected in 1-2 and 3% of cases, respectively. The standard treatment for testicular cancer is orchifuniculectomy and that for synchronous or metachronous cancer is organ-saving treatment, testectomy.</p><p>The paper describes a clinical case of multiple primary metachronous testicular cancer. A 24-year-old patient underwent surgery (orchifuniculectomy) and received 4 courses of BEP polychemotherapy for embryonal carcinoma of the left testicle at the P.A. Herzen Moscow Oncology Research Institute. After 55 months, a dynamic control examination diagnosed a 9-mm tumor in his single right testis that was thereafter resected. Its histological examination revealed embryonal carcinoma with solitary structures in the immature teratoma. Following 22 months, a control examination showed a recurrence of the disease, for which orchifuniculectomy of the single right testis, followed by hormone replacement therapy, was performed. The follow-up period was 80 months; no recurrence is now observed.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>testicular cancer</kwd><kwd>bilateral testicular cancer</kwd><kwd>testicular intraepithelial neoplasia</kwd><kwd>germ-cell testicular tumors</kwd><kwd>orchifuniculectomy</kwd><kwd>testectomy</kwd><kwd>testicular biopsy</kwd><kwd>hormone replacement therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак яичка</kwd><kwd>билатеральный рак яичек</kwd><kwd>тестикулярная интраэпителиальная неоплазия</kwd><kwd>герминогенные опухоли яичка</kwd><kwd>орхфуникулэктомия</kwd><kwd>резекция яичка</kwd><kwd>биопсия яичка</kwd><kwd>гормональная заместительная терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Заридзе Д.Г. Профилактика рака, руководство для врачей. М.: ИМА-пресс, 2009.</mixed-citation><mixed-citation xml:lang="ru">Заридзе Д.Г. Профилактика рака, руководство для врачей. М.: ИМА-пресс, 2009.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Чиссов В.И., Дарьялова С.Л. Клинические рекомендации. Онкология. М.: ГЭО-ТАР-Медиа, 2006.</mixed-citation><mixed-citation xml:lang="ru">Чиссов В.И., Дарьялова С.Л. Клинические рекомендации. Онкология. М.: ГЭО-ТАР-Медиа, 2006.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В.Старинского. М., 2012.</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В.Старинского. М., 2012.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Dijkstra S.S., Witjes J.A. A patient with bilateral testicular cancer. Ned Tijdschr Geneeskd 2012;156(11):A3392.</mixed-citation><mixed-citation xml:lang="ru">Dijkstra S.S., Witjes J.A. A patient with bilateral testicular cancer. Ned Tijdschr Geneeskd 2012;156(11):A3392.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. McGlynn K.A., Devesa S.S., Sigurdso n A.J. et al. Trends in the incidence of testicular germ cell tumours in the United States. Cancer 2003;97(1):63–70. http://www.ncbi.nlm.nih.gov/pubmed/12491506</mixed-citation><mixed-citation xml:lang="ru">McGlynn K.A., Devesa S.S., Sigurdso n A.J. et al. Trends in the incidence of testicular germ cell tumours in the United States. Cancer 2003;97(1):63–70. http://www.ncbi.nlm.nih.gov/pubmed/12491506</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Che M., Tamboli P., Ro J.Y. et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA 2002 Sep 15;95(6):1228–33.</mixed-citation><mixed-citation xml:lang="ru">Che M., Tamboli P., Ro J.Y. et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA 2002 Sep 15;95(6):1228–33.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Moller H., Prener A., Skakkebaek N.E. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control 1996;7(2):264–74. http://www.ncbi.nlm.nih.gov/pubmed/8740739</mixed-citation><mixed-citation xml:lang="ru">Moller H., Prener A., Skakkebaek N.E. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control 1996;7(2):264–74. http://www.ncbi.nlm.nih.gov/pubmed/8740739</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Weestergaard T., Olsen J.H., Frisch M. et al. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer 1996;66(5):627–31. http://www.ncbi.nlm.nih.gov/pubmed/8647624</mixed-citation><mixed-citation xml:lang="ru">Weestergaard T., Olsen J.H., Frisch M. et al. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer 1996;66(5):627–31. http://www.ncbi.nlm.nih.gov/pubmed/8647624</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Géczi L., Gomez F., Bak M., Bodrogi I. The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. 2003 May;129(5):309–15. Epub 2003 May 14.</mixed-citation><mixed-citation xml:lang="ru">Géczi L., Gomez F., Bak M., Bodrogi I. The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. 2003 May;129(5):309–15. Epub 2003 May 14.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Weissbach L. Organ Preserving Surgery of Malignant Germ Cell Tumors. J Urol 1995;153:90–3.</mixed-citation><mixed-citation xml:lang="ru">Weissbach L. Organ Preserving Surgery of Malignant Germ Cell Tumors. J Urol 1995;153:90–3.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Heidenreich A., Bonfig R., Derschum W. et al. A conservative approach to bilateral testicular germ cell tumors. J Urol 1995;153:10–3.</mixed-citation><mixed-citation xml:lang="ru">Heidenreich A., Bonfig R., Derschum W. et al. A conservative approach to bilateral testicular germ cell tumors. J Urol 1995;153:10–3.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Dieckmann K.P., Kulejewski M., Pichlmeier U., Loy V. Albertinen-Krankenhaus Hamburg, Urologische Abteilung, Germany. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. 2007 Jan;51(1):175–83; discussion 183–5. Epub 2006 Jun 13.</mixed-citation><mixed-citation xml:lang="ru">Dieckmann K.P., Kulejewski M., Pichlmeier U., Loy V. Albertinen-Krankenhaus Hamburg, Urologische Abteilung, Germany. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. 2007 Jan;51(1):175–83; discussion 183–5. Epub 2006 Jun 13.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Dieckmann K.P., Classen J., Souchon R., Loy V. Management of testicular intraepithelial neoplasia (TIN) – a review based on the principles of evidence-based medicine. 2001 Jan 15;113(1–2):7–14.</mixed-citation><mixed-citation xml:lang="ru">Dieckmann K.P., Classen J., Souchon R., Loy V. Management of testicular intraepithelial neoplasia (TIN) – a review based on the principles of evidence-based medicine. 2001 Jan 15;113(1–2):7–14.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Heidenreich A., Moul J.W. Department of Urology and Pediatric Urology, Phillips University, Marburg, Germany. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Urol Ann 2011;3(3):115–8.</mixed-citation><mixed-citation xml:lang="ru">Heidenreich A., Moul J.W. Department of Urology and Pediatric Urology, Phillips University, Marburg, Germany. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Urol Ann 2011;3(3):115–8.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Heidenreich A., Weissbach L., Höltl W. et al. German Testicular Cancer Study Group. Department of Urology, Philipps-University Marburg, Marburg, Krankenhaus Am Urban, Berlin, Germany.Organ sparing surgery for malignant germ cell tumor of the testis. 2001 Dec;166(6):2161–5.</mixed-citation><mixed-citation xml:lang="ru">Heidenreich A., Weissbach L., Höltl W. et al. German Testicular Cancer Study Group. Department of Urology, Philipps-University Marburg, Marburg, Krankenhaus Am Urban, Berlin, Germany.Organ sparing surgery for malignant germ cell tumor of the testis. 2001 Dec;166(6):2161–5.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Von der Maase H., Giwercman A., Skakkebaek N.E. Radiation treatment of carcinoma-in-situ of testis. Lancet 1986;1:624–5.</mixed-citation><mixed-citation xml:lang="ru">Von der Maase H., Giwercman A., Skakkebaek N.E. Radiation treatment of carcinoma-in-situ of testis. Lancet 1986;1:624–5.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Fizazi K., Oldenburg J., Dunant A. et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2008;19(2):259–64. http://www.ncbi.nlm.nih.gov/pubmed/18042838</mixed-citation><mixed-citation xml:lang="ru">Fizazi K., Oldenburg J., Dunant A. et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2008;19(2):259–64. http://www.ncbi.nlm.nih.gov/pubmed/18042838</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Hendry W.F., Norman A., Nicholls J. et al. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 2000;86(1):89–93. http://www.ncbi.n lm.nih.gov/pubmed/10886090</mixed-citation><mixed-citation xml:lang="ru">Hendry W.F., Norman A., Nicholls J. et al. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 2000;86(1):89–93. http://www.ncbi.n lm.nih.gov/pubmed/10886090</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Dieckmann K.P., Loy V., Buttner P. Prevalence of bilateral germ cell tumours and early detection based on contralateral testicular intraepithelial neoplasia. Br J Urol 1993;71(3):340–5. http://www.ncbi.nlm.nih.gov/pubmed/8386582</mixed-citation><mixed-citation xml:lang="ru">Dieckmann K.P., Loy V., Buttner P. Prevalence of bilateral germ cell tumours and early detection based on contralateral testicular intraepithelial neoplasia. Br J Urol 1993;71(3):340–5. http://www.ncbi.nlm.nih.gov/pubmed/8386582</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Tandstad T., Dahl O., Cohn-Cedermar k G. et al. Risk-adapted treatment in clinical stage 1 (CS1), nonseminomatous germ cell testicular cancer (NSGCT), the SWENOTECA management program. Heidenreich A. BJU Int 2009;104(9 Pt B):1346–50. Review.PMID: 19840011 [PubMed – indexed for MEDLINE].</mixed-citation><mixed-citation xml:lang="ru">Tandstad T., Dahl O., Cohn-Cedermar k G. et al. Risk-adapted treatment in clinical stage 1 (CS1), nonseminomatous germ cell testicular cancer (NSGCT), the SWENOTECA management program. Heidenreich A. BJU Int 2009;104(9 Pt B):1346–50. Review.PMID: 19840011 [PubMed – indexed for MEDLINE].</mixed-citation></citation-alternatives></ref></ref-list></back></article>
